Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

Original publication

DOI

10.1016/j.vaccine.2009.05.003

Type

Journal article

Journal

Vaccine

Publication Date

24/06/2009

Volume

27 Suppl 2

Pages

B30 - B41

Keywords

Humans, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup A, Neisseria meningitidis, Serogroup B, Neisseria meningitidis, Serogroup C, Neisseria meningitidis, Serogroup W-135, Sepsis, United States, Vaccines, Conjugate